Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 2:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 185 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: PEG Control Clear all
Not listed Phase 4 Interventional Accepts healthy volunteers

A Trial Comparing Bowel Preparation and Patient Tolerability of Miralax Versus Golytely

NCT00889655
View directory record Official record
Conditions
Colonoscopy
Interventions
Golytely (polyethylene glycol), MiraLax (polyethylene glycol 3350)
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years to 90 Years
Enrollment
432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 28, 2009 · Synced Sep 25, 2026, 2:51 PM EDT
Completed Not applicable Interventional

Directly Observed Hepatitis C Treatment in Methadone Clinics

NCT01442311
View directory record Official record
Conditions
Hepatitis C, Medication Adherence
Interventions
enhanced DOT (both pegylated interferon alfa-2a and ribavirin), standard DOT (PEG-DOT control arm)
Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Sep 25, 2026, 2:51 PM EDT
Not listed Phase 3 Interventional

A Study to Investigate Efficacy and Safety of Weekly PEG-somatropin (GenSci004) in Treatment Naive Children With Growth Hormone Deficiency

NCT06007417
View directory record Official record
Conditions
GHD
Interventions
GenSci004, Genotropin
Drug
Lead sponsor
Changchun GeneScience Pharmaceutical Co., Ltd.
Industry
Eligibility
3 Years to 12 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2023 · Synced Sep 25, 2026, 2:51 PM EDT
Completed Not applicable Interventional

Testing How Well Magnesium Citrate Capsules Work as Preparation for a Colonoscopy

NCT03247595
View directory record Official record
Conditions
Colonoscopy
Interventions
Magnesium Citrate Capsules, Polyethylene Glycol 3350, Dulcolax Tablets
Dietary Supplement · Other
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Sep 25, 2026, 2:51 PM EDT
Completed Phase 2 Interventional Results available

Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501

NCT01355289
View directory record Official record
Conditions
Thrombocytopenia
Interventions
Avatrombopag, Placebo, Pegylated interferon (PEG-IFN), Telaprevir, Ribavirin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Los Angeles, California • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 21, 2018 · Synced Sep 25, 2026, 2:51 PM EDT
Active, not recruiting Phase 2 Interventional

Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion)

NCT04789044
View directory record Official record
Conditions
Peripheral Nerve Injuries
Interventions
NTX-001
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Baltimore, Maryland • Camden, New Jersey • Charlotte, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 25, 2026, 2:51 PM EDT
Completed Phase 2 Interventional

A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)

NCT00008463
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Ribavirin, Interferon alfa-2a, Peginterferon alfa-2a
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
24
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 25, 2026, 2:51 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition

NCT05664477
View directory record Official record
Conditions
Menopause, Cognitive Change, Brain Disorder, Metabolic
Interventions
PhytoSERM, Placebo
Dietary Supplement · Drug
Lead sponsor
Roberta Brinton
Other
Eligibility
45 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
Tucson, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 25, 2026, 2:51 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Neuromodulation of the Cortex and Spinal Cord

NCT06586437
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Clinical Assessments, Brain-Spinal Cord fMRI, Hoffmann Reflex Assessments, MEG Imaging, Transcutaneous Current Stimulation
Behavioral
Lead sponsor
Father Flanagan's Boys' Home
Other
Eligibility
11 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Boys Town, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 25, 2026, 2:51 PM EDT
Completed Phase 3 Interventional

A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

NCT00160602
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
17
States / cities
Montgomery, Alabama • Sun City West, Arizona • Palm Desert, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Sep 25, 2026, 2:51 PM EDT
Completed Phase 3 Interventional

BLI-800-302: BLI-800 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy

NCT00503815
View directory record Official record
Conditions
Colonoscopy
Interventions
BLI-800, Polyethylene glycol 3350 based bowel preparation
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
10
States / cities
Anaheim, California • Orange, California • Jackson, Mississippi + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2007 · Synced Sep 25, 2026, 2:51 PM EDT
Not listed Phase 1 Interventional

Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)

NCT03588715
View directory record Official record
Conditions
HIV, HIV/AIDS, HIV-1 Infection
Interventions
Pegylated Interferon alpha 2b (peg-IFN-α2b), 3BNC117 + 10-1074
Drug
Lead sponsor
Luis Montaner
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Sep 25, 2026, 2:51 PM EDT
Terminated Phase 3 Interventional Results available

Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease

NCT00349752
View directory record Official record
Conditions
Crohn's Disease
Interventions
certolizumab pegol 400 mg, Placebo
Biological · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
54
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Sep 25, 2026, 2:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults

NCT05755620
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Quadrivalent Inactivated Vaccine, Sodium Chloride, 0.9%, VRC-FLUNPF099-00-VP (H1ssF_3928)
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 25, 2026, 2:51 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU

NCT01889862
View directory record Official record
Conditions
Phenylketonuria (PKU)
Interventions
BMN165 20mg/day, BMN165 40mg/day, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years to 70 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
29
States / cities
La Jolla, California • Oakland, California • Aurora, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Sep 25, 2026, 2:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy

NCT01170754
View directory record Official record
Conditions
Colon Cancer
Interventions
PEG-3350 and Gatorade, Golytely 4 liters
Drug
Lead sponsor
Temple University
Other
Eligibility
40 Years to 75 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Sep 25, 2026, 2:51 PM EDT
Completed Phase 2 Interventional

PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery

NCT00276523
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
PEG-interferon alfa-2b, Conventional surgery, Neoadjuvant therapy
Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Sep 25, 2026, 2:51 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Pilot Study for Toxicity Evaluation of HIV Rectal Microbicides

NCT00389311
View directory record Official record
Conditions
HIV Infections
Interventions
Normosol-R, Nonoxynol-9, Gastrointestinal instrumentation
Drug · Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Sep 25, 2026, 2:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Optimization of the Bowel Preparation Regimen for the PillCam® COLON 2 Capsule Endoscopy Procedure

NCT02481219
View directory record Official record
Conditions
Colorectal Cancer Screening
Interventions
PillCam® COLON 2 procedure-CONTROL, Senna tablets, PEG, Metoclopramide, Erythromycin, SUPREP oral sulfate solution, Bisacodyl, SUPREP oral sulfate solution with Gastrografin
Device · Drug
Lead sponsor
Medtronic - MITG
Industry
Eligibility
50 Years to 75 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
6
States / cities
Anniston, Alabama • Indianapolis, Indiana • Dayton, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Sep 25, 2026, 2:51 PM EDT
Not listed Not applicable Interventional

Umbilical Cord Care for the Prevention of Colonization

NCT01893060
View directory record Official record
Conditions
Line Insertion Site, Central Line-associated Bloodstream Infection (CLABSI)
Interventions
Povidone-Iodine, Chlorhexidine gluconate, Pluronic Cream, control
Drug · Other
Lead sponsor
University of Virginia
Other
Eligibility
Up to 7 Days
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Sep 25, 2026, 2:51 PM EDT
Completed Phase 2 Interventional Results available

Herbal Mouthrinse for Oral Mucositis Study

NCT01898091
View directory record Official record
Conditions
Oral Mucositis
Interventions
Neem Mouthrinse, Placebo Mouthrinse
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Sep 25, 2026, 2:51 PM EDT
Completed Phase 2 Interventional Results available

Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients

NCT01188772
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Sofosbuvir, Placebo to match sofosbuvir, PEG, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
22
States / cities
Montgomery, Alabama • Anaheim, California • Coronado, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 25, 2026, 2:51 PM EDT
Completed Phase 3 Interventional Results available

Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis

NCT01087788
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
CZP 200 mg Q2W, CZP 400 mg Q4W, Placebo
Biological · Other
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
27
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 25, 2026, 2:51 PM EDT
Completed Phase 3 Interventional Results available

A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

NCT00077623
View directory record Official record
Conditions
Anemia
Interventions
epoetin alfa or beta, methoxy polyethylene glycol-epoetin beta (Mircera)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
17
States / cities
Hot Springs, Arkansas • Los Angeles, California • Riverside, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Sep 25, 2026, 2:51 PM EDT